Comparative Pharmacology
Head-to-head clinical analysis: AVANAFIL versus STAXYN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVANAFIL versus STAXYN.
AVANAFIL vs STAXYN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of phosphodiesterase type 5 (PDE5), enhancing nitric oxide-mediated relaxation of smooth muscle in the corpus cavernosum, increasing cGMP levels, and promoting penile erection.
Selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). By inhibiting PDE5, sildenafil increases intracellular cGMP levels in the corpus cavernosum, enhancing the relaxant effect of nitric oxide (NO) on smooth muscle cells, thereby facilitating penile erection in response to sexual stimulation.
100 mg orally once daily, taken 30-60 minutes before sexual activity. Maximum dosing frequency: once daily.
10 mg sublingually as needed, 30–60 minutes before sexual activity. Maximum 1 dose per 24 hours.
None Documented
None Documented
Clinical Note
moderateAvanafil + Torasemide
"Avanafil may increase the antihypertensive activities of Torasemide."
Clinical Note
moderateAvanafil + Travoprost
"Avanafil may increase the antihypertensive activities of Travoprost."
Clinical Note
moderateAvanafil + Unoprostone
"Avanafil may increase the antihypertensive activities of Unoprostone."
Clinical Note
moderateAvanafil + Hydrochlorothiazide
"Avanafil may increase the antihypertensive activities of Hydrochlorothiazide."
Terminal elimination half-life approximately 6-8 hours. Clinical context: Supports once-daily dosing; steady-state reached within 5 days with no accumulation at FDA-approved dose.
Terminal elimination half-life is approximately 4-5 hours; clinically, no accumulation with once-daily dosing
Primarily hepatic metabolism via CYP3A4 and CYP2C9, with metabolites excreted in feces (approximately 82-90%) and urine (approximately 6-8% as unchanged drug and minor metabolites).
Renal (approximately 90% as metabolites, <2% unchanged); fecal (10%)
Category C
Category C
PDE5 Inhibitor
PDE5 Inhibitor